{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:10:03Z","timestamp":1784923803256,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Institute of Health","award":["UM1-AI120176"],"award-info":[{"award-number":["UM1-AI120176"]}]},{"name":"National Institute of Health","award":["R61AI149665"],"award-info":[{"award-number":["R61AI149665"]}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.xphs.2020.08.003","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T11:51:22Z","timestamp":1597060282000},"page":"3480-3489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Controlled Solvent Removal from Antiviral Drugs and Excipients\u00a0in\u00a0Solution Enables the Formation of Novel Combination\u00a0Multi-Drug-Motifs in Pharmaceutical Powders Composed of\u00a0Lopinavir, Ritonavir and Tenofovir"],"prefix":"10.1016","volume":"109","author":[{"given":"Jesse","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"McConnachie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2020.08.003_bib1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection: epidemiology, pathogenesis, treatment, and prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.xphs.2020.08.003_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1126\/science.277.5322.112","article-title":"Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease","volume":"277","author":"Autran","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.xphs.2020.08.003_bib3","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.xphs.2020.08.003_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1468-1293.2008.00618.x","article-title":"Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy","volume":"9","author":"Maitland","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.xphs.2020.08.003_bib5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3109\/10837450.2012.660699","article-title":"Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms","volume":"18","author":"Desai","year":"2013","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.xphs.2020.08.003_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijpharm.2018.05.008","article-title":"A comparative study between hot-melt extrusion and spray-drying for the manufacture of anti-hypertension compatible monolithic fixed-dose combination products","volume":"545","author":"Kelleher","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.08.003_bib7","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s10461-019-02701-7","article-title":"A conjoint analysis of the acceptability of targeted long-acting injectable Antiretroviral therapy among persons living with HIV in the U.S","volume":"24","author":"Simoni","year":"2019","journal-title":"AIDS Behav"},{"key":"10.1016\/j.xphs.2020.08.003_bib8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/COH.0000000000000164","article-title":"Formulation and pharmacology of long-acting rilpivirine","volume":"10","author":"Williams","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.xphs.2020.08.003_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/COH.0000000000000168","article-title":"Formulation and pharmacology of long-acting cabotegravir","volume":"10","author":"Trezza","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.xphs.2020.08.003_bib10","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.addr.2007.09.010","article-title":"Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective","volume":"60","author":"Chen","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2020.08.003_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","article-title":"Nanostructured lipid matrices for improved microencapsulation of drugs","volume":"242","author":"Muller","year":"2002","journal-title":"Int J Pharm"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2020.08.003_bib12","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations","volume":"54","author":"Muller","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2020.08.003_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.addr.2007.10.013","article-title":"Advances in lipid nanodispersions for parenteral drug delivery and targeting","volume":"60","author":"Constantinides","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2020.08.003_bib14","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.xphs.2018.07.032","article-title":"Three HIV drugs, atazanavir, ritonavir, and tenofovir, coformulated in drug-combination nanoparticles exhibit long-acting and lymphocyte-targeting properties in nonhuman primates","volume":"107","author":"Perazzolo","year":"2018","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.08.003_bib15","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.xphs.2018.03.005","article-title":"Long-acting profile of 4 drugs in 1 anti-HIV nanosuspension in nonhuman primates for 5 weeks after a single subcutaneous injection","volume":"107","author":"McConnachie","year":"2018","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.08.003_bib16","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1097\/QAD.0000000000000421","article-title":"Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood","volume":"28","author":"Freeling","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.xphs.2020.08.003_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/aid.2014.0210","article-title":"Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates","volume":"31","author":"Freeling","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.xphs.2020.08.003_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00126334-200312010-00005","article-title":"Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques","volume":"34","author":"Kinman","year":"2003","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.xphs.2020.08.003_bib19","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/jps.24046","article-title":"Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles","volume":"103","author":"Duan","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.08.003_bib20","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/QAD.0000000000001405","article-title":"Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma","volume":"31","author":"Kraft","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.xphs.2020.08.003_bib21","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1021\/acs.molpharmaceut.7b00203","article-title":"Multidrug, anti-HIV amorphous solid dispersions: nature and mechanisms of impacts of drugs on each other's solution concentrations","volume":"14","author":"Arca","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2020.08.003_bib22","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.drudis.2007.09.005","article-title":"Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs","volume":"12","author":"Vasconcelos","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.xphs.2020.08.003_bib23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.addr.2009.11.019","article-title":"Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs","volume":"62","author":"Sharma","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2020.08.003_bib24","first-page":"100035","article-title":"Amorphous solid dispersion formation via solvent granulation - a case study with ritonavir and lopinavir","volume":"1","author":"Trasi","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.08.003_bib25","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.xphs.2018.09.008","article-title":"Impact of method of preparation of amorphous solid dispersions on mechanical properties: comparison of coprecipitation and spray drying","volume":"108","author":"Hou","year":"2019","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.08.003_bib26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jconrel.2012.03.013","article-title":"Drug nanocrystals: in vivo performances","volume":"160","author":"Gao","year":"2012","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2020.08.003_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2018.07.012","article-title":"Electrohydrodynamic atomization and spray-drying for the production of pure drug nanocrystals and co-crystals","volume":"131","author":"Sverdlov Arzi","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2020.08.003_bib28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/10837450.2019.1669181","article-title":"Dual drug nanocrystals loaded microparticles for fixed dose combination of simvastatin and ezetimibe","volume":"25","author":"Nandi","year":"2020","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.xphs.2020.08.003_bib29","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1021\/acs.molpharmaceut.8b00122","article-title":"Qualitative and quantitative characterization of composition heterogeneity on the surface of spray dried amorphous solid dispersion particles by an advanced surface analysis platform with high surface sensitivity and superior spatial resolution","volume":"15","author":"Bhujbal","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2020.08.003_bib30","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1021\/jp2020148","article-title":"Coarse-grained model for PEGylated lipids: effect of PEGylation on the size and shape of self-assembled structures","volume":"115","author":"Lee","year":"2011","journal-title":"J\u00a0Phys Chem B"},{"key":"10.1016\/j.xphs.2020.08.003_bib31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijpharm.2014.08.062","article-title":"The fate of ritonavir in the presence of darunavir","volume":"475","author":"Nguyen","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.08.003_bib32","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1002\/jps.24528","article-title":"Thermodynamics of highly supersaturated aqueous solutions of poorly water-soluble drugs-impact of a second drug on the solution phase behavior and implications for combination products","volume":"104","author":"Trasi","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.08.003_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jconrel.2018.02.003","article-title":"Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation","volume":"275","author":"Kraft","year":"2018","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2020.08.003_bib34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin Pharm"},{"key":"10.1016\/j.xphs.2020.08.003_bib35","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200101050-00002","article-title":"ABT-378\/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results","volume":"15","author":"Murphy","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.xphs.2020.08.003_bib36","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.xphs.2020.01.016","article-title":"Integration of computational and experimental approaches to elucidate mechanisms of first-pass lymphatic drug sequestration and long-acting pharmacokinetics of the injectable triple-HIV drug combination TLC-ART 101","volume":"109","author":"Perazzolo","year":"2020","journal-title":"J\u00a0Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920304342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920304342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:29:49Z","timestamp":1758360589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354920304342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0022354920304342"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2020.08.003","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controlled Solvent Removal from Antiviral Drugs and Excipients\u00a0in\u00a0Solution Enables the Formation of Novel Combination\u00a0Multi-Drug-Motifs in Pharmaceutical Powders Composed of\u00a0Lopinavir, Ritonavir and Tenofovir","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2020.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of the American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}